about
Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41The M-T Hook Structure Is Critical for Design of HIV-1 Fusion InhibitorsDiscovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranesConjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its actionA unified conformational selection and induced fit approach to protein-peptide dockingA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroPepComposer: computational design of peptides binding to a given protein surfaceIdentification of fragments targeting an alternative pocket on HIV-1 gp41 by NMR screening and similarity searching.Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubilityBiophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.Enhanced potency of bivalent small molecule gp41 inhibitors.NMR-assisted computational studies of peptidomimetic inhibitors bound in the hydrophobic pocket of HIV-1 glycoprotein 41.Prediction of the interaction of HIV-1 integrase and its dicaffeoylquinic acid inhibitor through molecular modeling approachBiochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor designSwapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infectionA suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors.Anti-antimicrobial peptides: folding-mediated host defense antagonists.Amphipathic properties of HIV-1 gp41 fusion inhibitors.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Evaluation of ligand-based NMR screening methods to characterize small molecule binding to HIV-1 glycoprotein-41.Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41.Synthetic peptides derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1 co-infection.Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.PinaColada: peptide-inhibitor ant colony ad-hoc design algorithm.The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.Effect of amphipathic HIV fusion inhibitor peptides on POPC and POPC/cholesterol membrane properties: a molecular simulation study.The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins.Cationic liposomes are possible drug-delivery systems for HIV fusion inhibitor sifuvirtideHIV vs. HIV: Turning HIV-Derived Peptides into Drugs
P2860
Q27666159-E5BC1EF4-122A-4CFC-AD4D-C3A03FB84E52Q27671434-CB1DE086-9343-4771-9E00-71EA77D3686BQ27678581-636E8A90-47C1-4D06-8E13-A48B3B16791EQ28473380-C27EBC7E-3CF1-487C-BE29-73F5A2C25921Q28485911-B679FDBC-D867-4E81-AB74-346C287B7309Q28487957-D718ADF1-267D-4028-9794-AEBE290BC98FQ28728917-CABC4D84-F2A4-4B15-AF1D-CF17F923C08CQ29048212-B228C0A3-63AD-49A6-8A35-CD27165634C5Q30660631-C4E94021-9A86-4C94-A07F-FDD1DC5130B6Q33713101-A88DC992-B23A-4E2E-B234-F6B30D299622Q33935016-8BE72664-A759-4E87-B768-DBFBD552C24DQ34149681-8346AB66-3514-4AB0-A5A0-0452578C6DAAQ34189558-F18FBD88-E878-46FF-8A25-9F22ADBFA482Q34546445-99A1A754-C750-4523-B730-1647BDCCB865Q34871486-99C8531A-A95C-4649-B7B0-8B430C377AB9Q34952453-3F097EE6-982F-4958-9804-61AA0828D496Q35563298-8A703262-1332-4DCB-B7C0-C57EC8ECA516Q36036157-EE48B391-277D-4E42-9858-AECF45EA18A2Q36297991-F99A6A6B-96BD-43B4-A67C-E39BCC0192ADQ37012373-E070C289-3535-43AE-9DCC-F24B4B484181Q37951610-57E1C31E-9E9C-43F3-AC9F-427E961093D9Q38574172-A4A49B9C-572D-4E37-97E7-EEF7DF8575B8Q38673747-69C92703-027F-4DF9-9D30-75D81F185582Q38992313-D6C9E7C5-A8E6-44A5-B34C-1EC3633E033FQ39375757-578C008A-DBCA-4A08-BB43-4BD93EBF1641Q39443459-873F83B8-7218-415D-A9A3-0A97793BB553Q39788518-4B01D0FF-F293-45A6-BD8E-E892CFB8875FQ40968142-5CE1E9F5-DF38-4289-AD8A-25A3FAB25422Q41770502-C411C0F6-D2BE-408C-BCEA-964C0E36A9C3Q42213760-5234B5F0-1890-4304-9EA5-3197B73BE988Q47144668-FAE17B17-65C9-4C1B-A292-0457D1FE1604Q57080724-5EAE9FF4-7551-42B2-9913-C007A0184848Q58626543-D1CBA2CF-C1BD-484B-84BD-3E44BCA89E23
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Peptides in the treatment of AIDS.
@en
Peptides in the treatment of AIDS.
@nl
type
label
Peptides in the treatment of AIDS.
@en
Peptides in the treatment of AIDS.
@nl
prefLabel
Peptides in the treatment of AIDS.
@en
Peptides in the treatment of AIDS.
@nl
P2860
P1476
Peptides in the treatment of AIDS.
@en
P2093
Fred Naider
Jacob Anglister
P2860
P304
P356
10.1016/J.SBI.2009.07.003
P577
2009-07-23T00:00:00Z